东富龙收盘下跌2.16%，滚动市盈率78.80倍，总市值117.86亿元

Company Overview - Dongfulong Technology Group Co., Ltd. specializes in providing pharmaceutical process, core equipment, and system engineering solutions for global pharmaceutical companies [1] - The main product segments include bioprocessing, formulation, engineering solutions, and food equipment engineering [1] Financial Performance - For Q1 2025, the company reported revenue of 1.137 billion yuan, representing a year-on-year increase of 2.58% [1] - The net profit for the same period was 20.1326 million yuan, showing a significant year-on-year decline of 68.87% [1] - The sales gross margin stood at 24.45% [1] Market Position - As of August 22, the company's stock closed at 15.39 yuan, down 2.16%, with a rolling price-to-earnings (PE) ratio of 78.80 times [1] - The total market capitalization is 11.786 billion yuan [1] - In comparison to the industry, the average PE ratio is 56.95 times, and the median is 40.49 times, placing Dongfulong at the 99th position in the industry ranking [1][2] Institutional Holdings - As of Q1 2025, there is one institutional holder of Dongfulong, which is a fund holding a total of 2.1845 million shares, valued at 2.9 million yuan [1]